1955-04-0

Basic information

• Product Name: methyl 3-(chlorocarbonyl)-5-nitrobenzoate
• Synonyms: methyl 3-(chlorocarbonyl)-5-nitrobenzoate;3-Chlorocarbonyl-5-nitrobenzoic acid methyl ester;Benzoic acid, 3-(chlorocarbonyl)-5-nitro-, Methyl ester
• CAS NO: 1955-04-0
• Molecular Formula: C₉H₆ClNO₅
• Molecular Weight: 243.60064
• EINECS: 217-789-4
• Mol File: 1955-04-0.mol

Chemical Properties

• Melting Point: 72.4-74.0 °C
• Boiling Point: 369.8 °C at 760 mmHg
• Flash Point: 177.5 °C
• Appearance: /
• Density: 1.471 g/cm³
• Vapor Pressure: 1.15E-05mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: methyl 3-(chlorocarbonyl)-5-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(chlorocarbonyl)-5-nitrobenzoate(1955-04-0)
• EPA Substance Registry System: methyl 3-(chlorocarbonyl)-5-nitrobenzoate(1955-04-0)

Safety Data

• Hazardous Substances Data: 1955-04-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 3-(chlorocarbonyl)-5-nitrobenzoate is used as a precursor in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. Its unique structure allows for the formation of new compounds through nucleophilic substitution reactions, making it a valuable building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, methyl 3-(chlorocarbonyl)-5-nitrobenzoate is used as a key intermediate in the synthesis of various drugs. Its reactivity and functional groups enable the development of new therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Industry:
Methyl 3-(chlorocarbonyl)-5-nitrobenzoate is also utilized in the agrochemical industry for the production of pesticides and other crop protection agents. Its chemical properties allow for the creation of effective compounds that can protect crops from pests and diseases.
Used in Dye and Pigment Production:
In the dye and pigment industry, methyl 3-(chlorocarbonyl)-5-nitrobenzoate is used as a starting material for the synthesis of various dyes, pigments, and other specialty chemicals. Its versatile structure contributes to the development of new colorants with unique properties and applications.

InChI:InChI=1/C9H6ClNO5/c1-16-9(13)6-2-5(8(10)12)3-7(4-6)11(14)15/h2-4H,1H3

Upstream product

• 1955-46-0 5-nitro-1,3-benzenedicarboxylic acid, monomethyl ester 
• 618-88-2 5-nitrobenzene-1,3-dicarboxylic acid 

Downstream Products

• 61493-99-0 DL-N-(3-Methoxycarbamoyl-5-nitrobenzoyl)-O-methylserin 
• 49755-96-6 N-Methylcarbamoylmethyl-5-nitro-isophthalamic acid methyl ester 
• 49756-06-1 N-Methyl-N-methylcarbamoylmethyl-5-nitro-isophthalamic acid methyl ester 
• 51739-67-4 N-(1-Methylcarbamoyl-propyl)-5-nitro-isophthalamic acid methyl ester 
• 51739-66-3 N-(1-Methylcarbamoyl-ethyl)-5-nitro-isophthalamic acid methyl ester 
• 49756-07-2 N-(2-Methylcarbamoyl-ethyl)-5-nitro-isophthalamic acid methyl ester 
• 60667-07-4 N-(2-Methoxy-1-methylcarbamoyl-ethyl)-5-nitro-isophthalamic acid methyl ester 
• 49755-97-7 N-(3-Methoxycarbonyl-5-nitro-benzoyl)-glycin 
• 53732-08-4 3-hydroxymethyl-5-nitrobenzoic acid methyl ester 
• 172899-78-4 methyl 3-formyl-5-nitrobenzoate 
• 194291-30-0 3-Benzoyl-5-nitro-benzoic acid methyl ester 
• 742101-77-5 2-acetyl-4-methylphenyl methyl 5-nitroisophthalate 
• 869096-81-1 methyl 3-(4-methoxybenzoyl)-5-nitromethylbenzoate 
• 914099-67-5 7-(3-methoxycarbonyl-5-nitro-benzoylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 

Relevant articles and documents

Contrast agent iopromide intermediate as well as preparation method and application thereof

The invention discloses a contrast agent iopromide intermediate as well as a preparation method and application thereof, and belongs to the technical field of organic chemistry. The iopromide intermediate is N-(2, 3-dihydroxy-propyl)-5-nitroisophthalic acid methyl ester. According to the preparation method, the iopromide intermediate is synthesized through two steps, the product obtained in the reaction in the step (1) can directly participate in the reaction in the step (2) without a complex purification process, the product obtained in the step (2) does not need a time-consuming, labor-consuming and money-consuming purification method such as column chromatography and does not need a recrystallization method which can cause a great loss of the product, the high-purity iopromide intermediate can be obtained only through simple extraction, the purity is larger than 99.5%, and the yield can reach 70-80%. Therefore, when the intermediate is used for preparing iopromide, the price of iopromide can be greatly reduced.

Preparation method and application of iopromide intermediate (by machine translation)

The invention relates to a preparation method of an iopromide intermediate and an application thereof in preparation of iopromide. The method comprises the following steps: compound VI compound is subjected to reduction reaction under the action of Raney nickel/hydrazine hydrate to obtain the compound V compound. The reaction is carried out under normal pressure, the operation is simple and safe, the generated intermediate impurities are less, and the reaction is more suitable for industrial production. The method is used for preparing iopromide, can avoid the generation of a diacylated by-product, can effectively reduce the generation of by-products in the preparation process, can be easily separated and purified, and can obtain high-purity iopromide with high yield. (by machine translation)

Preparation methods of iopromide and intermediate of iopromide

The application of the invention relates to preparation methods of iopromide and an intermediate of the iopromide. The method specifically comprises the following steps: conducting a reduction reaction, an iodination reaction and an acylation reaction on a compound shown in the formula VI to prepare a compound shown in the formula III, and further preparing to obtain the iopromide. The method notonly avoids the generation of double acylation byproducts, but also effectively reduces the generation of byproducts in the preparation process, the intermediate is easy to separate and purify, and ahigh-purity product is obtained at a relatively high yield.

BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS

There is provided compounds of formula I, wherein Y, ring A, Da, Db, D2, D3, L1, Y1, L2, Y2, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.

Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold

A potential anti-HIV and HCV drug candidate is highly desirable as coinfection has become a worldwide public health challenge. A potent compound based on a tetrabutoxy-calix[4]arene scaffold that possesses dual inhibition for both HIV and HCV is described. Structural activity relationship studies demonstrate the effects of lower-rim alkylation in maintaining cone conformation and upper-rim interacting head groups on the calix[4]arene play key roles for its potent dual antiviral activities.

BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided the use of a compound of formula (I): wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS

The invention relates to novel macrocyclic compounds of the Formula (I) in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: The discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis

Conformational analysis of trans-1,2-disubstituted cyclohexane CCR3 antagonist 2 revealed that the cyclohexane linker could be replaced by an acyclic syn-α-methyl-β-hydroxypropyl linker. Synthesis and biological evaluation of mono- and disubstituted propyl linkers support this conformational correlation. It was also found that the α-methyl group to the urea lowered protein binding and that the β-hydroxyl group lowered affinity for CYP2D6. Ab initio calculations show that the α-methyl group governs the spatial orientation of three key functionalities within the molecule. α-Methyl-β-hydroxypropyl urea 31 with a chemotaxis IC50 = 38 pM for eosinophils was chosen to enter clinical development for the treatment of asthma.

New anti-viral drugs for the treatment of the common cold

Human Rhinovirus (HRV) is the most important aetiologic agent of common cold in adults and children. HRV is a single-stranded, positive sense RNA virus and, despite the high level of conservation among different serotypes, sequence alignment of viral protease 3C with mammalian protease reveals no homology. Thus, protease 3C is an optimal target for the development of anti-HRV agents. In the present work we investigated the design, the synthesis and the development of new potential reversible inhibitors against HRV protease 3C. Docking studies on the crystallized structure of HRV2 protease 3C led us to the design and the synthesis of a series of 3,5 disubstituted benzamides able to act as analogues of the substrate. We also developed 1,3,5 trisubstituted benzamides where aromatic substitutions on the aryl ring led us to investigate the importance of π-π interaction on the stabilization of protease 3C-inhibitor complex. All structures were tested for enzymatic inhibition on HRV14 protease 3C. Results highlighted the inhibitory activity of compounds 13, 14, and 20 (91%, 81%, and 85% at 10 μM, respectively), with the latter exhibiting an ID50 (dose that inhibits 50% of the viral cytopathic effect) on HRV-14 = 25 μg/ml.

Macrocyclic Compounds Useful as Bace Inhibitors

The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.